Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

•High-dose anakinra (up to 12 mg/kg/day) for refractory cytokine release syndrome (CRS)/immune effector cell-associated neurotoxicity syndrome (ICANS) was safe.•Higher anakinra dose may be associated with faster CRS/ICANS resolution and was independently associated with lower treatment-related mortality.